Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.
You may also be interested in...
Cannabis Products: FDA Asks Dosing, Research Incentive Questions
The public hearing on cannabis and cannabis-derivative products also included calls for Good Manufacturing Practices to be imposed.
Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid
Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.
GW's Epidiolex Approval Encouraging For Pharma-grade Cannabinoid Pipeline
Beyond Epidiolex for severe epilepsy, cannabinoid candidates are in development for a range of diseases, including acute pain, graft-versus-host disease, scleroderma, schizophrenia, pain and substance use disorder.